Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

R

O'Brien MP, Hunt PW, Kitch DW, et al. "A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy." Open Forum Infect Dis. 2017;4(1):ofw278.
J Kilby M, R Bucy P, Mildvan D, et al. "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)." J. Infect. Dis.. 2006;194(12):1672-6.
Fischl MA, Collier AC, A Mukherjee L, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS. 2007;21(3):325-33.
Dubé MP, Chan ES, Lake JE, et al. "A Randomized, Double-Blinded, Placebo-Controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection." Clin. Infect. Dis.. 2018.
Jacobson JM, Wang H, Bordi R, et al. "A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2014;66(4):399-406.
Peters MG, Andersen J, Lynch P, et al. "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127." Hepatology. 2006;44(5):1110-6.
Erlandson KM, Taejaroenkul S, Smeaton L, et al. "A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings." Open Forum Infect Dis. 2015;2(3):ofv095.
Riddler SA, Zheng L, Durand CM, et al. "Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART." Open Forum Infect Dis. 2018;5(10):ofy242.
Albrecht M, A Mukherjee L, Tierney C, et al. "A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study." HIV Clin Trials. 2011;12(4):201-14.
Court R, Gordon M, Cohen K, et al. "Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy." Int. J. Antimicrob. Agents. 2016;48(2):158-62.
La Rosa AM, Harrison LJ, Taiwo B, et al. "Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study." Lancet HIV. 2016;3(6):e247-58.
Simoni JM, Huh D, Wilson IB, et al. "Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study." J. Acquir. Immune Defic. Syndr.. 2012;60(5):466-72.
Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. "Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095." J. Acquir. Immune Defic. Syndr.. 2007;46(5):547-54.
Ribaudo HJ, Smith KY, Robbins GK, et al. "Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis." Clin. Infect. Dis.. 2013;57(11):1607-17.
Yin MT, Chan ES, Brown TT, et al. "Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation." AIDS. 2017;31(17):2337-2344.
Mollan KR, Tierney C, Hellwege JN, et al. "Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants." J. Infect. Dis.. 2017;216(5):554-564.

P

Safren SA, Biello KB, Smeaton L, et al. "Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial." PLoS ONE. 2014;9(8):e104178.
Paul RH, Yiannoutsos CT, Miller EN, et al. "Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity." J Neuropsychiatry Clin Neurosci. 2007;19(3):283-92.
Kalayjian RC, Wu K, Evans S, et al. "Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2014;67(1):30-5.
Gupta SK, Komarow L, Gulick RM, et al. "Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects." J. Infect. Dis.. 2009;200(4):614-8.
Hitti J, Andersen J, McComsey G, et al. "Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084." Am. J. Obstet. Gynecol.. 2007;196(4):331.e1-7.
Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W. "Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa." AIDS Res Treat. 2011;2011:769627.
Stein JH, Ribaudo HJ, Hodis HN, et al. "A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness." AIDS. 2015;29(14):1775-83.
Currier JS, Kendall MA, W Henry K, et al. "Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults." AIDS. 2007;21(9):1137-45.

Pages